Avadel (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with narcolepsy.
Learn more about us at www.avadel.com and follow us on Twitter at @AvadelPharma.
At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with narcolepsy.
Learn more about us at www.avadel.com and follow us on Twitter at @AvadelPharma.
Location: Ireland, Leinster, Dublin
Employees: 51-200
Founded date: 1990
Investors 1
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
Mentions in press and media 13
| Date | Title | Description |
| 25.02.2026 | Alkermes plc Announces CEO Succession Plan | Alkermes plc (Nasdaq: ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes’ Board of Directors (the Board) appointed Blair Jackson, Alkermes’ curren... |
| 14.11.2025 | Stocks making the biggest premarket moves: Warner Bros. Discovery, Cidara Therapeutics, Avadel Pharmaceuticals and more | - |
| 13.11.2025 | Nasdaq closes higher, snapping three-day losing streak as tech stocks recover some ground | The Nasdaq Composite rebounded on Friday as investors bought up shares of key technology stocks a day after the group led Wall Street to its worst day in more than a month. The tech-heavy Nasdaq gained 0.13% to finish at 22,900.59, snapping... |
| 23.10.2025 | Ирландская Alkermes покупает американского производителя лекарств от бессонницы Avadel за $2,1 млрд | Сделка открывает для Alkermes доступ на рынок медицины сна благодаря препарату Lumryz компании Avadel, одобренному для лечения катаплексии или чрезмерной дневной сонливости у пациентов от семи лет и старше, страдающих нарколепсией — заболев... |
| 08.07.2025 | Narcolepsy Network Announces its 38th Annual Conference | A Weekend of Learning, Community and Hope CAMAS, Wash., July 8, 2025 /PRNewswire-PRWeb/ -- Narcolepsy Network is delighted to announce its 38th Annual Conference, taking place Friday, October 24 through Sunday, October 26, 2025, at the Roya... |
| 15.05.2025 | Vivo Capital: Public Fund Closed With Over $740 Million In Commitments | Vivo Capital—a leading global investment firm focused exclusively on healthcare and life sciences—announced it has closed the third cycle of its Vivo Opportunity Fund and its affiliates with over $740 million in commitments. The Public Fund... |
| 24.11.2024 | Navigating the Sleep Science Frontier: A New Era for Hypersomnolence Treatment | Sleep is a complex puzzle. For many, it’s a sanctuary. For others, it’s a battleground. Central disorders of hypersomnolence, like narcolepsy and idiopathic hypersomnia, turn sleep into a foe. These conditions cause excessive daytime sleepi... |
| 18.11.2024 | State-of-the-science webinar will explore narcolepsy and hypersomnia | Sleep Research Society Foundation Free webinar from the Sleep Research Society Foundation is Monday, Dec. 2. DARIEN, Ill., Nov. 18, 2024 /PRNewswire-PRWeb/ -- The Sleep Research Society Foundation is hosting a state-of-the-science webinar, ... |
| 13.06.2024 | Global Gene's RARE-X and Sleep Consortium Launch Sleep Data Collection Initiative to Accelerate Development of Therapies | Global Genes The Sleep Data Collection Initiative, the first consortium on the RARE-X platform for the collection and sharing of patient-owned data, brings together patient advocacy organizations, researchers, and drug developers looking to... |
| 11.06.2024 | QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors | Industry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals Former Karuna CFO Brown brings more than... |
Show more